HUT49358A - Process for producing phosphorous compounds, pharmaceutical compositions comprising same as active ingredient and intermediaries - Google Patents

Process for producing phosphorous compounds, pharmaceutical compositions comprising same as active ingredient and intermediaries

Info

Publication number
HUT49358A
HUT49358A HU882614A HU261488A HUT49358A HU T49358 A HUT49358 A HU T49358A HU 882614 A HU882614 A HU 882614A HU 261488 A HU261488 A HU 261488A HU T49358 A HUT49358 A HU T49358A
Authority
HU
Hungary
Prior art keywords
intermediaries
active ingredient
pharmaceutical compositions
same
phosphorous compounds
Prior art date
Application number
HU882614A
Other languages
Hungarian (hu)
Other versions
HU205125B (en
Inventor
Donald S Karanewsky
Scott A Biller
Eric M Gordon
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Publication of HUT49358A publication Critical patent/HUT49358A/en
Publication of HU205125B publication Critical patent/HU205125B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/32—Esters thereof
    • C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/3211—Esters of acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/36—Amides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44—Amides thereof
    • C07F9/4403—Amides thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4407—Amides of acyclic saturated acids which can have further substituents on alkyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HU882614A 1987-05-22 1988-05-20 Process for producing phosphorous compounds and pharmaceutical compositions comprising same HU205125B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5328187A 1987-05-22 1987-05-22
US10968087A 1987-10-19 1987-10-19

Publications (2)

Publication Number Publication Date
HUT49358A true HUT49358A (en) 1989-09-28
HU205125B HU205125B (en) 1992-03-30

Family

ID=26731667

Family Applications (1)

Application Number Title Priority Date Filing Date
HU882614A HU205125B (en) 1987-05-22 1988-05-20 Process for producing phosphorous compounds and pharmaceutical compositions comprising same

Country Status (24)

Country Link
JP (1) JP2680347B2 (en)
KR (1) KR880013958A (en)
CN (1) CN88103091A (en)
AU (1) AU610591B2 (en)
BE (1) BE1004193A3 (en)
CH (1) CH676984A5 (en)
DE (1) DE3817375C2 (en)
DK (1) DK277488A (en)
ES (1) ES2009918A6 (en)
FI (1) FI89493C (en)
FR (1) FR2615508B1 (en)
GB (1) GB2205837B (en)
GR (1) GR1000959B (en)
HU (1) HU205125B (en)
IE (2) IE63760B1 (en)
IL (1) IL86464A (en)
IT (1) IT1217685B (en)
NL (1) NL8801330A (en)
NO (1) NO882218L (en)
NZ (1) NZ224733A (en)
PH (1) PH25350A (en)
PL (1) PL154877B1 (en)
PT (1) PT87539B (en)
SE (1) SE503210C2 (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86463A (en) * 1987-05-22 1994-10-07 Squibb & Sons Inc Phosphorus-containing hmg-coa reductase inhibitor compounds and pharmaceutical compositions containing the same
CA2007643A1 (en) * 1989-02-01 1990-08-01 Donald S. Karanewsky Combination of an hmg coa reductase inhibitor and a squalene synthetase inhibitor and method for lowering serum cholesterol using such combination
CA2042526A1 (en) * 1990-06-11 1991-12-12 Adeoye Y. Olukotun Method for preventing a second heart attack employing an hmg coa reductase inhibitor
US5202327A (en) * 1991-07-10 1993-04-13 E. R. Squibb & Sons, Inc. Phosphorus-containing hmg-coa reductase inhibitors
GB9126144D0 (en) * 1991-12-10 1992-02-12 British Bio Technology Compounds
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
EP1113801A4 (en) 1998-09-17 2002-10-02 Bristol Myers Squibb Co METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION
US6774112B2 (en) 2001-04-11 2004-08-10 Bristol-Myers Squibb Company Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
CA2463908A1 (en) 2001-10-18 2003-04-24 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US6806381B2 (en) 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
ATE469645T1 (en) 2002-10-23 2010-06-15 Bristol Myers Squibb Co GLYCINENITRIL BASED INHIBITORS OF DIPEPTIDYLPEPTIDASE IV
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US8158362B2 (en) 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
CA2558766A1 (en) 2004-03-05 2005-09-22 The Trustees Of The University Of Pennsylvania The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
US7145040B2 (en) 2004-07-02 2006-12-05 Bristol-Myers Squibb Co. Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
AR051446A1 (en) 2004-09-23 2007-01-17 Bristol Myers Squibb Co C-ARYL GLUCOSIDS AS SELECTIVE INHIBITORS OF GLUCOSE CONVEYORS (SGLT2)
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7635699B2 (en) 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7589088B2 (en) 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7368458B2 (en) 2005-01-12 2008-05-06 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7220859B2 (en) 2005-01-12 2007-05-22 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076598A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US20060160850A1 (en) 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
EP2527337A1 (en) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
AR056155A1 (en) 2005-10-26 2007-09-19 Bristol Myers Squibb Co ANTAGONISTS OF NON-BASIC MELANINE CONCENTRATION HORMONE RECEIVER 1
WO2007053819A2 (en) 2005-10-31 2007-05-10 Bristol-Myers Squibb Company Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
US20100022457A1 (en) 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
EP2089355A2 (en) 2006-11-01 2009-08-19 Brystol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof
AR065809A1 (en) 2007-03-22 2009-07-01 Bristol Myers Squibb Co PHARMACEUTICAL FORMULATIONS CONTAINING AN SGLT2 INHIBITOR
PE20090696A1 (en) 2007-04-20 2009-06-20 Bristol Myers Squibb Co CRYSTALLINE FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING THEM
CN101820757A (en) 2007-06-01 2010-09-01 普林斯顿大学托管委员会 By regulating host cell metabolic pathways treatment virus infections
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
WO2009018065A2 (en) 2007-07-27 2009-02-05 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
AU2008302570B2 (en) 2007-09-20 2012-05-31 Irm Llc Compounds and compositions as modulators of GPR119 activity
PE20091928A1 (en) 2008-05-29 2009-12-31 Bristol Myers Squibb Co HAVE HYDROXYSUSTITUTED PYRIMIDINES AS NON-BASIC MELANIN-CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS
AU2010229653A1 (en) 2009-03-27 2011-10-20 Astrazeneca Ab Methods for preventing major adverse cardiovascular events with DPP-IV inhibitors
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
JP2013507366A (en) 2009-10-09 2013-03-04 アイアールエム・リミテッド・ライアビリティ・カンパニー Compounds and compositions as GPR119 activity modulators
US8871264B2 (en) 2009-11-13 2014-10-28 Astrazeneca Ab Immediate release tablet formulations
ES2689107T3 (en) 2009-11-13 2018-11-08 Astrazeneca Ab Bilayer tablet formulations
CA2780938A1 (en) 2009-11-13 2011-05-19 Bristol-Myers Squibb Company Reduced mass metformin formulations
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
EP2558461B1 (en) 2010-04-14 2015-12-02 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
CA2804926C (en) 2010-07-09 2019-01-08 James Trinca Green Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
TWI631963B (en) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
PT3489226T (en) 2012-11-20 2021-03-02 Lexicon Pharmaceuticals Inc Inhibitors of sodium glucose cotransporter 1
US9593113B2 (en) 2013-08-22 2017-03-14 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
CN104610262B (en) * 2013-11-01 2017-06-06 上海医药工业研究院 Biphenyl compound, intermediate, preparation method, pharmaceutical composition and its application
TW201702271A (en) 2015-04-30 2017-01-16 哈佛大學校長及研究員協會 Anti-AP2 antibodies and antigen binding agents to treat metabolic disorders
EA202190226A1 (en) 2018-07-19 2021-06-16 Астразенека Аб METHODS FOR TREATMENT OF HFpEF USING DAPAGLIFLOSIN AND COMPOSITIONS CONTAINING IT
WO2020068661A1 (en) 2018-09-26 2020-04-02 Lexicon Pharmaceuticals, Inc. Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA828650B (en) * 1981-12-01 1983-09-28 Hunt Chem Corp Philip A Herbicidal compositions and method using phosphonalkanoic acids, esters and salts thereof
FR2596393B1 (en) * 1986-04-01 1988-06-03 Sanofi Sa HYDROXY-3 DIHYDROXYOXOPHOSPHORIO-4 BUTANOIC ACID DERIVATIVES, THEIR PREPARATION PROCESS, THEIR USE AS MEDICAMENTS AND THE COMPOSITIONS CONTAINING THEM
IL86463A (en) * 1987-05-22 1994-10-07 Squibb & Sons Inc Phosphorus-containing hmg-coa reductase inhibitor compounds and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
SE8801903L (en) 1988-11-23
IE63760B1 (en) 1995-06-14
IE930324L (en) 1988-11-22
NZ224733A (en) 1990-12-21
DK277488A (en) 1988-11-23
IT8820682A0 (en) 1988-05-20
GR880100331A (en) 1989-02-23
PT87539A (en) 1989-05-31
DE3817375C2 (en) 1997-04-30
JP2680347B2 (en) 1997-11-19
DK277488D0 (en) 1988-05-20
IE881543L (en) 1988-11-22
HU205125B (en) 1992-03-30
JPS6456689A (en) 1989-03-03
FR2615508B1 (en) 1994-11-25
NL8801330A (en) 1988-12-16
BE1004193A3 (en) 1992-10-13
FI89493C (en) 1993-10-11
DE3817375A1 (en) 1988-12-08
SE503210C2 (en) 1996-04-22
NO882218D0 (en) 1988-05-20
NO882218L (en) 1988-11-23
CN88103091A (en) 1988-12-21
IL86464A (en) 1993-06-10
PH25350A (en) 1991-05-13
FI89493B (en) 1993-06-30
IT1217685B (en) 1990-03-30
PL154877B1 (en) 1991-09-30
CH676984A5 (en) 1991-03-28
ES2009918A6 (en) 1989-10-16
FI882384A0 (en) 1988-05-20
GR1000959B (en) 1993-03-16
GB8811929D0 (en) 1988-06-22
PT87539B (en) 1992-09-30
FR2615508A1 (en) 1988-11-25
IL86464A0 (en) 1988-11-15
AU610591B2 (en) 1991-05-23
SE8801903D0 (en) 1988-05-20
GB2205837B (en) 1991-11-20
PL272597A1 (en) 1989-03-06
FI882384A (en) 1988-11-23
GB2205837A (en) 1988-12-21
KR880013958A (en) 1988-12-22
AU1650888A (en) 1988-11-24

Similar Documents

Publication Publication Date Title
HUT49358A (en) Process for producing phosphorous compounds, pharmaceutical compositions comprising same as active ingredient and intermediaries
HUT46654A (en) Process for producing substituted basic 2-amino-tetralin derivatives and pharmaceutical compositions comprising the same as active ingredient
HUT47131A (en) Process for producing steroid-5alpha-reductase inhibitors and pharmaceutical compositions comprising them as active ingredient
HUT53359A (en) Process for producing pharmaceutical compositions comprising oxooxazolinidyl cyclopentano benzene derivatives as active ingredient
HUT51222A (en) Process for producing 9-halogen-/z/-prostaglandin derivatives and pharmaceutical compositions comprising such active ingredient
HUT45844A (en) Pesticides comprising imidazole derivatives as active ingredient and process for producing the active ingredients
HUT44904A (en) Herbicides comprising 3-phenyl-uracyl derivatives as active ingredient and process for producing the active ingredients and intermediaries thereof
HUT53873A (en) Insecticides comprising nitro compounds as active ingredient and process for producing the active ingredients
HUT45850A (en) Insecticides comprising azolinone derivatives as active ingredient and process for producing the active ingredients
HUT48609A (en) Process for producing kumaran derivatives and pharmaceutical compositions comprising same as active ingredient
HUT49625A (en) Process for producing macrolid compounds and pharmaceutical compositions comprising such active ingredient
HUT48605A (en) Fungicides comprising hydroxyalkylazolyl derivatives as active ingredient and process for producing the active ingredient
HUT47123A (en) Process for producing phosphorous compounds and pharmaceutical compositions comprising them as active ingredient, as well as their intermediates
HUT47937A (en) Process for producing indoloquinoxaline derivatives and pharmaceuticals comprising these compounds as active ingredient
HUT53897A (en) Process for producing benzopyran derivatives and pharmaceutical compositions comprising such compounds as active ingredient
HUT48217A (en) Pesticides comprising 5-methylamino-1-arylpyrazole derivatives as active ingredient and process for producing the active ingredients
HUT49598A (en) Process for producing chromone derivatives and pharmaceutical compositions comprising same as active ingredient
HUT46660A (en) Process for producing 3-alkoxy-2-amino-propyl-amines and pharmaceutical compositions comprising the same as active ingredient
HUT47233A (en) Process for producing pharmaceutical comprising phenol derivatives as active ingredient and for producing the active ingredients
HUT47210A (en) Insecticide compositions and process for producing benzoyl-urea derivatives as active components
HUT49596A (en) Herbicides comprising iminophenylthiazolidine derivatives as actie ingredient and process for producing the active ingredients
HUT54358A (en) Process for producing substituted 1,3,5-triazinetrione derivatives and medical compositions comprising such compounds as active ingredient
HUT48613A (en) Process for producing carbamoyloxylabdane derivatives, their intermediaries and pharmaceutical compositions comprising such compounds as active ingredient
HUT63151A (en) Process for producing new benzimidazole-2-sulfonamide and imidazopyuridine-2-sylfonamide derivatives, as well as pharmaceutical compositions comprising same as active ingredient
HUT48871A (en) Herbicidal compositions and process for producing substituted tetrahydrophtalimide derivatives applicable as active ingredient

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees